

## Review

# The life cycle of chondrocytes in the developing skeleton

Lillian Shum and Glen Nuckolls

Cartilage Biology and Orthopaedics Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA

**Correspondence:** Dr Glen H Nuckolls, Cartilage Biology and Orthopaedics Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 6 Center Drive, Building 6, Room 324, MSC2745, Bethesda, MD 20892-2745, USA. Tel: +1 301 435 8427; fax: +1 301 480 3313; e-mail: [gknuckolls@nih.gov](mailto:gknuckolls@nih.gov)

Received: 13 August 2001

*Arthritis Res* 2002, 4:94-106

Revisions requested: 5 September 2001

Revisions received: 14 September 2001

Accepted: 19 September 2001

© 2002 BioMed Central Ltd

Published: 8 November 2001

(Print ISSN 1465-9905; Online ISSN 1465-9913)

## Abstract

Cartilage serves multiple functions in the developing embryo and in postnatal life. Genetic mutations affecting cartilage development are relatively common and lead to skeletal malformations, dysfunction or increased susceptibility to disease or injury. Characterization of these mutations and investigation of the molecular pathways in which these genes function have contributed to an understanding of the mechanisms regulating skeletal patterning, chondrogenesis, endochondral ossification and joint formation. Extracellular growth and differentiation factors including bone morphogenetic proteins, fibroblast growth factors, parathyroid hormone-related peptide, extracellular matrix components, and members of the hedgehog and Wnt families provide important signals for the regulation of cell proliferation, differentiation and apoptosis. Transduction of these signals within the developing mesenchymal cells and chondrocytes results in changes in gene expression mediated by transcription factors including Smads, Msx2, Sox9, signal transducer and activator of transcription (STAT), and core-binding factor alpha 1. Further investigation of the interactions of these signaling pathways will contribute to an understanding of cartilage growth and development, and will allow for the development of strategies for the early detection, prevention and treatment of diseases and disorders affecting the skeleton.

**Keywords:** cartilage, chondrogenesis, endochondral ossification, limb bud, neural crest cells

## Introduction

Cartilage is a connective tissue of diverse embryonic origin, that serves multiple prenatal and postnatal functions. Cartilage provides structural support for the early embryo, forms a template for developing endochondral bones, provides for rapid postnatal growth of the skeleton, cushions the joints, allows for flexible facial structure, and repairs fractured bones. Chondrocytes exhibit a life cycle of proliferation, differentiation, maturation, and apoptosis; the rate of each of these processes is dependent on tem-

poral and spatial cues within the body. Identifying and characterizing these cues will reveal the molecular basis of cartilage form and function. Mutations or deregulation of these determinants of chondrogenesis and cartilage development can lead to skeletal malformation, limited skeletal function, or predisposition to injury. Congenital skeletal malformations are common and can be caused by a number of factors: inherited individual or multiple gene mutations; or acquired gene-environment interactions. Recent progress in linkage analysis and positional cloning

has identified many genetic mutations associated with human skeletal syndromes or predispositions to certain skeletal diseases (Table 1). Sequencing the human genome also allows for the identification of the genetic loci of many bone- and cartilage-associated genes that serve as candidate links with additional skeletal disorders. Because of genetic background or gene-environment interactions, single gene mutations can cause different disorders. Furthermore, the same phenotype can be the result of mutations in different genes [1]. Complex diseases that are subject to multifactorial influences, such as osteoarthritis [2,3] provide the greatest challenges ahead. An understanding of the mechanisms that regulate chondrogenesis and cartilage development will, therefore, contribute to early gene-based detection of diseases and disorders that affect cartilage, and will provide the necessary foundation for novel prevention and treatment strategies, such as gene therapy and tissue engineering.

### Genetic and biomechanical determinants of chondrogenesis

Although chondrocytes appear to be a uniform cell type comprising the majority of the cells in cartilage, the origins and elaborations of the cartilage lineage are diverse. Chondrocytes arise from cranial neural crest cells (CNCCs) of the neural ectoderm, cephalic mesoderm, sclerotome of the paraxial mesoderm, or somatopleure of the lateral plate mesoderm. Terminal differentiation of chondrocytes results in different types of cartilage: hyaline; elastic; and fibrous. Chondrocyte differentiation, therefore, provides unique opportunities for the study of 'what, when and how' a repertoire of morphogenetic signals are integrated into the developmental program. A number of molecules have been shown to function in cartilage formation. These include classes of extracellular ligands and their cognate receptors and cytoplasmic transducers [4], nuclear receptors [5], transcription factors or DNA-binding proteins [6], matrix proteins [7], matrix modifiers including matrix metalloproteinases [8], adhesion molecules [9] and the cytoskeleton [10]. The functions of these molecules have been reviewed in the literature cited and references therein. Although much is known about the gene products that characterize the cartilage phenotype, very little is known about the combinations of gene products that reflect the genesis of the cartilage cell lineage. Furthermore, the growth and development of the skeleton are particularly susceptible to the influence of biomechanical forces [11]. Mechanical loading regulates the shape, repair, regeneration, and senescence of the skeleton. Mechanical signals are transduced through the extracellular matrices, modify cell-matrix and cell-cell interactions, and impact on transcriptional responses. The interplay, therefore, between genetic and biomechanical determinants controls the integrity of cartilage produced both *in vivo* and *in vitro* [12].

### Mesenchymal cell condensation

Chondroprogenitor mesenchymal cells aggregate into chondrogenic nodules as a necessary step in chondrocyte differentiation. This condensation process is dependent on signals initiated by cell-matrix and cell-cell adhesion, and these signals are modified by the cell's response to growth and differentiation factors in the extracellular environment. Condensation is hallmarked by changes in cell adhesion and cytoskeletal architecture [9,13]. The roles of N-cadherin, fibronectin, syndecans, tenascins, thrombospondins, neural cell adhesion molecule, focal adhesion kinase and paxillin in chondrogenic condensation have been reported. These molecules are expressed in restricted temporal and spatial patterns that correlate with chondroprogenitor cell condensation. Perturbations of the functions of these molecules leads to disruption in cell aggregation and inhibition of normal cartilage formation. Cell-cell and cell-matrix interactions activate cytoplasmic kinases, phosphatases and GTPases that can, in turn, be modulated by signaling from growth and differentiation factors such as the bone morphogenetic proteins (BMPs) and Wnts [14-16]. Although chondrogenesis is regulated by combinatorial signaling of a large number of factors, cell condensation can be regarded as the major event of the cell's commitment to the cartilage lineage, after which tissue-specific transcription factors and structural proteins begin to accumulate.

### Bone morphogenetic proteins

BMPs are a pleiotropic group of extracellular ligands, first coined due to the ability of demineralized bone matrix (containing BMPs) to induce bone formation when injected into muscular compartments of animals [17]. Since then, a large number of molecules of the BMP family, and its superfamily, the transforming growth factor-betas (TGF- $\beta$ s) have been cloned and identified, with mammalian BMP2 and BMP4 being the prototypes of the *Drosophila* homologue, decapentaplegic [18,19]. BMPs signal through transmembrane serine threonine kinase receptors [20]. There are two types of receptors, type I and type II, each having a number of subtypes and varying affinities to the different BMPs. Downstream from the receptors are various cytoplasmic and nuclear transducers, both positive and negative [21]. Over the past three decades since the discovery of BMPs, their ability to induce ectopic bone and cartilage formation and the mechanism of induction have been meticulously dissected [22]. BMPs, however, have been demonstrated to function in multiple systems and stages of development [19]. The diversity and specificity, therefore, of cellular competence and response towards BMPs remain to be topics of intense investigation. The pleiotropic actions of BMPs can be concentration-dependent, and BMP signaling can be regulated by positive and negative cellular feedback events [20]. Concomitantly, BMP signals are modulated by BMP binding proteins and other growth and differentia-

**Table 1**

**Selected genes causal to skeletal diseases and disorders**

OMIM #	Gene name	Gene symbol	Diseases and disorders
114290	Sry-related HMG-box gene 9	SOX9	Acampomelic campomelic dysplasia Campomelic dysplasia Campomelic dysplasia with autosomal sex reversal
120110	Collagen, type X alpha-1	COL10A1	Metaphyseal chondrodysplasia, Schmid type Spondylometaphyseal dysplasia, Japanese type
120140	Collagen, type II alpha-1	COL2A1	Achondrogenesis, type II Achondrogenesis-hypochondrogenesis, type II Hypochondrogenesis Kniest dysplasia Osteoarthritis with mild chondrodysplasia Spondyloepimetaphyseal dysplasia, Strudwick type Spondyloepiphyseal dysplasia, various types Spondylometaphyseal dysplasia, congenital type Spondyloperipheral dysplasia Stickler syndrome, type I Wagner syndrome
120150	Collagen, type I alpha-1	COL1A1	Ehlers–Danlos syndrome, types I and VIIA Osteogenesis imperfecta, types I, II, III, and IV
120160	Collagen, type I alpha-2	COL1A2	Ehlers–Danlos syndrome, type VII-B Osteogenesis imperfecta, types II, III, and IV Osteogenesis imperfecta/Ehlers–Danlos crossover syndrome Marfan syndrome, atypical
120180	Collagen, type III alpha-1	COL3A1	Arterial and aortic aneurysms Ehlers–Danlos syndrome, types III and IV
120190	Collagen, type V alpha-2	COL5A2	Ehlers–Danlos syndrome, types I and II
120215	Collagen, type V alpha-1	COL5A1	Ehlers–Danlos syndrome, types I, II, and mixed type
120260	Collagen, type IX alpha-2	COL9A2	Epiphyseal dysplasia, multiple, type 2 Intervertebral disc disease
120270	Collagen, type IX alpha-3	COL9A3	Epiphyseal dysplasia, multiple, type 3 Epiphyseal dysplasia, multiple, with myopathy
120280	Collagen, type XI alpha-1	COL11A1	Stickler syndrome, type II Marshall syndrome
120290	Collagen, type XI alpha-2	COL11A2	Sensorineural deafness, autosomal dominant nonsyndromic Otospondylomegaepiphyseal dysplasia Stickler syndrome, type III Weissenbacher–Zweymuller syndrome
120360	Matrix metalloproteinase 2	MMP2	Osteolysis, idiopathic, Saudi type
121050	Fibrillin 2	FBN2	Contractural arachnodactyly, congenital
123101	Muscle segment homeobox 2	MSX2	Craniosynostosis, Boston-type Parietal foramina 1
125505	Deoxyribonuclease I	DNASE1	Systemic lupus erythematosus susceptibility
133700	Exostosin 1	EXT1	Exostoses, multiple, type 1 Chondrosarcoma
133701	Exostosin 2	EXT2	Exostoses, multiple, type II
134797	Fibrillin 1	FBN1	Marfan syndrome, various types Ectopia lentis, familial Marfanoid skeletal syndrome Mass syndrome Shprintzen–Goldberg syndrome

*Continued opposite*

**Table 1****Continued**

OMIM #	Gene name	Gene symbol	Diseases and disorders
134934	Fibroblast growth factor receptor 3	<i>FGFR3</i>	Achondroplasia Crouzon syndrome with acanthosis nigricans Hypochondroplasia Muenke syndrome Multiple myeloma Saddan dysplasia Thanatophoric dysplasia, types I and II
136350	Fibroblast growth factor receptor 1	<i>FGFR1</i>	Pfeiffer syndrome
139250	Growth hormone 1	<i>GH1</i>	Growth hormone deficiency Isolated growth hormone deficiency, type I Kowarski syndrome
139320	Guanine nucleotide-binding protein, alpha-stimulating activity polypeptide 1	<i>GNAS1</i>	Mccune–Albright syndrome Albright hereditary osteodystrophy Pituitary adenoma, ACTH-secreting
142461	Heparan sulfate proteoglycan of basement membrane, perlecan	<i>HSPG2</i>	Schwartz–Jampel syndrome, type 1 Dyssegmental dysplasia, Silverman–Handmaker type
142958	Homeobox A11	<i>HOXA11</i>	Radioulnar synostosis with amegakaryocytic thrombocytopenia
147620	Interleukin 6	<i>IL6</i>	Interleukin 6 polymorphism associated with systemic onset juvenile rheumatoid arthritis
154870	Matrix gamma-carboxyglutamic acid protein	<i>MGP</i>	Keutel syndrome
156845	Microphthalmia-associated transcription factor	<i>MITF</i>	Waardenburg syndrome, type IIA Tietz albinism–deafness syndrome
157660	Mitochondrial RNA-processing endoribonuclease (RNA component of)	<i>RMRP</i>	Cartilage–hair hypoplasia
168450	Parathyroid hormone	<i>PTH</i>	Hypoparathyroidism
168468	Parathyroid hormone receptor 1	<i>PTHRI</i>	Metaphyseal chondrodysplasia, Murk Jansen type Chondrodysplasia, Blomstrand type
176943	Fibroblast growth factor receptor 2	<i>FGFR2</i>	Apert syndrome Beare–Stevenson cutis gyrata syndrome Craniosynostosis, nonsyndromic unicoronal Crouzon syndrome Jackson–Weiss syndrome Pfeiffer syndrome Saethre–Chotzen syndrome
190180	Transforming growth factor, beta-1	<i>TGFB1</i>	Camurati–Engelmann disease
193500	Paired box gene 3	<i>PAX3</i>	Waardenburg syndrome, types I, II, and III Waardenburg syndrome with meningomyelocele Rhabdomyosarcoma, alveolar Craniofacial–deafness–hand syndrome
203500	Homogentisate 1,2-dioxygenase	<i>HGD</i>	Alkaptonuria
217000	Complement component 2	<i>C2</i>	Complement component 2 deficiency
222600	Solute carrier family 26, member 2	<i>SLC26A2</i>	Achondrogenesis, type IB Atelosteogenesis, type II Diastrophic dysplasia
249100	Familial Mediterranean fever gene	<i>MEFV</i>	Familial Mediterranean fever
277900	ATPase, Cu(2+)-transporting, beta polypeptide	<i>ATP7B</i>	Wilson Disease
300202	Sedlin	<i>SEDL</i>	Spondyloepiphyseal dysplasia, late
300300	Bruton agammaglobulinemia tyrosine kinase	<i>BTK</i>	Agammaglobulinemia, X-linked associated with septic arthritis

Continued overleaf

**Table 1**

**Continued**

OMIM #	Gene name	Gene symbol	Diseases and disorders
308000	Hypoxanthine guanine phosphoribosyltransferase 1	<i>HPRT1</i>	Gout, HPRT-related Lesch-Nyhan syndrome
311850	Phosphoribosylpyrophosphate synthetase I	<i>PRPS1</i>	Gout, PRPS-related
312865	Short stature homeobox	<i>SHOX</i>	Short stature, idiopathic Leri-Weill dyschondrosteosis Langer mesomelic dysplasia
600211	Runt-related transcription factor 2	<i>RUNX2</i>	Cleidocranial dysplasia
600310	Cartilage oligomeric matrix protein	<i>COMP</i>	Epiphyseal dysplasia Pseudoachondroplasia
600725	Sonic hedgehog	<i>SHH</i>	Holoprosencephaly 3
600726	Indian hedgehog	<i>IHH</i>	Brachydactyly type A1
600856	Cyclin-dependent kinase inhibitor 1C	<i>CDKN1C</i>	Beckwith-Wiedemann syndrome
600946	Growth hormone receptor	<i>GHR</i>	Laron syndrome Short stature, autosomal dominant and idiopathic
601105	Cathepsin K	<i>CTSK</i>	Pycnodysostosis
601146	Growth/differentiation factor 5	<i>GDF5</i>	Acromesomelic dysplasia, Hunter-Thompson type Brachydactyly, type C Chondrodysplasia, Grebe type
601199	Calcium-sensing receptor	<i>CASR</i>	Hypercalciuric hypercalcemia Hypercalciuric hypocalcemia Hyperparathyroidism Hypocalcemia Hypocalciuric hypercalcemia Hypoparathyroidism, various types
601309	Patched	<i>PTCH</i>	Basal cell nevus syndrome Basal cell carcinoma, sporadic
601769	Vitamin D receptor	<i>VDR</i>	Vitamin D-resistant rickets, type II
602109	Matrilin 3	<i>MATN3</i>	Multiple epiphyseal dysplasia
602337	Receptor tyrosine kinase-like Orphan receptor 2	<i>ROR2</i>	Brachydactyly, type B1 Robinow syndrome, autosomal recessive
602365	Cathepsin C	<i>CTSC</i>	Papillon-Lefevre syndrome Haim-Munk syndrome
602727	Chloride channel 7	<i>CLCN7</i>	Osteopetrosis, Autosomal Recessive, Infantile Malignant
602991	Noggin	<i>NOG</i>	Symphalangism, proximal Multiple synostoses syndrome 1
603400	Wnt1-inducible signaling pathway protein 3	<i>WISP3</i>	Arthropathy, progressive pseudorheumatoid of childhood
603499	Tumor necrosis factor receptor superfamily, 11A	<i>TNFRSF11A</i>	Expansile osteolysis, familial Paget disease of bone 2
604142	Tyro protein tyrosine kinase-binding protein	<i>TYROBP</i>	Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy
604283	Proteoglycan 4	<i>PRG4</i>	Camptodactyly-arthropathy-coxa vara-pericarditis syndrome
604592	T cell immune regulator 1	<i>TCIRG1</i>	Osteopetrosis, autosomal recessive
604831	Ellis-Van Creveld syndrome gene	<i>EVC</i>	Ellis-Van Creveld syndrome Weyers acrodistal dysostosis
605145	Ank	<i>ANKH</i>	Cranio-metaphyseal dysplasia, autosomal dominant
605380	Fibroblast growth factor 23	<i>FGF23</i>	Hypophosphatemic rickets, autosomal dominant
605420	Aristaless-like 4,	<i>ALX4</i>	Parietal foramina 2
605740	Sclerostin	<i>SOST</i>	Sclerosteosis

Mutations in a number of genes have been shown to cause congenital skeletal disorders, often with defects in cartilage formation as the primary basis. Others predispose the individual towards skeletal diseases such as arthritis. The completed sequence of the human genome opens the door for rapid identification of additional genetic mutations associated with human diseases and disorders. Functional genomics and the characterization of molecular mechanisms bridging genotypes to phenotypes are our challenges to realize solutions for the prevention, detection, diagnosis and therapy of these diseases and disorders. Data extracted from Online Mendelian Inheritance in Man (OMIM) [113].

tion factors, resulting in combinatorial signaling and divergent outcomes dependent on the modifiers, which can be either genetic or environmental [23].

### Sox9

The Sry-type, high-mobility group (HMG)-box containing transcription factor SOX9 comes closest to serving the function of a master regulator of the chondrocyte lineage of any molecule yet characterized. Sox9 expression is directly induced by BMP signaling [24–26]. In humans, SOX9 haploinsufficiency (Online Mendelian Inheritance in Man [OMIM] number 114290) results in campomelic dysplasia (a lethal skeletal malformation syndrome) with XY sex reversal [27]. During embryogenesis, Sox9 is expressed in all chondroprogenitors, coincident with the expression of type II collagen. Sox9 regulates chondrogenesis through binding to essential DNA sequence motifs in chondrocyte-specific enhancer elements of the type II and type XI collagen genes and the cartilage-derived retinoic-acid-sensitive protein. Sox9 can even bind to, and activate, these DNA enhancer sequences in cartilage genes that have been transfected into nonchondrocytes [28–30]. Mouse embryonic stem cells with null mutations of Sox9 do not form cartilage in teratomas [31]. Animals that are heterozygous null for Sox9 exhibit defects in all cartilage primordia and present a phenotype similar to human campomelic dysplasia [32]. The phosphorylation of Sox9 by cAMP-dependent protein kinase A in response to parathyroid hormone-related peptide (PTHrP) signaling regulates the binding of Sox9 to responsive elements in the collagen promoters [33,34]. Furthermore, Sox9 is known to form complexes with L-Sox5 and Sox6, and may also interact with other chondrocyte-associated transcription factors [35]. The regulation of this key player in chondrogenesis, therefore, is at the level of expression, protein modification, complex formation, and transcriptional activation.

### Patterning and cell fate determination

Chondrogenesis can be divided into two interdependent processes: patterning; and cell fate determination. Pattern formation is the process during which number, size, and shape of the cartilaginous template is delineated and established. Cell fate determination is the process by which the combinatorial interactions of genetic and environmental factors serve to direct the developmental progression of a cell lineage. Cell fate is progressively restricted, and tissue specificity is gradually committed. The actions of these determinants are dependent upon concentration, time, and position. Patterning and cell fate determination are governed by a series of tissue interactions, which include interactions between adjacent components of segmental structures, or between juxtaposed epithelium and mesenchyme. Chondrogenesis during craniofacial and limb development best illustrates the complexity and hierarchy of regulatory mechanisms underlying the developmental program. During vertebrate

morphogenesis, CNCCs, as well as limb bud mesenchymal cells, respond to BMP4 [36]. Depending on the timing of exposure to BMP4, these mesenchymal cells may undergo apoptosis or chondrogenesis. The orchestration of the apoptotic and chondrogenic response results in the formation and delineation of cartilaginous structures in the developing face and limbs. Studies have shown that the regulation of BMP4-mediated divergent morphogenetic outcome is dependent on both positive and negative modulators, at the level of ligands, cytoplasmic signals, and transcription factors.

### Craniofacial development

Cartilages of the craniofacial region are largely derived from CNCCs [37]. CNCCs are a specialized population of ectodermal cells in origin, and arise from the lateral margin of the developing hindbrain. At the early somite stage of the embryo, the hindbrain is segmented into compartments called rhombomeres. CNCCs that are generated from the hindbrain are thus segment-specific, and these cells undergo epithelial to mesenchymal transformation, leave the crest and migrate towards the forming face. The cells populate the branchial arches, expand, and eventually differentiate into cartilage and several other cell types. A series of experiments showed that CNCCs are responsive to BMP4 and, depending on the stage of development, there can be different outcomes. Instrumental to the differential responses is a homeodomain transcription factor, Msx2, which mediates craniofacial and limb morphogenesis [38,39]. A gain of function mutation in the human *MSX2* gene (OMIM 123101) causes Boston-type craniosynostosis, while loss of function mutations in this gene cause parietal foramina type I [40]. Msx2 is present in all stages of CNCC development: formation; migration; and differentiation. In the developing rhombomeres, BMP4 and Msx2 are coexpressed in rhombomeres 3 and 5 and correlate with extensive CNCC apoptosis observed in these rhombomeres, which results in limited contribution of CNCC to the craniofacial skeleton [41]. Apoptosis is the mechanism of eliminating CNCCs, which are not necessary for differentiation, and the occurrence of apoptosis in alternate segments of the hindbrain serves to pattern the migrating CNCCs into three major streams. In these early premigratory crest cells, BMP4 induces Msx2 expression and causes apoptosis [41]. Overexpression of Msx2 along the cephalic neural tube results in increased apoptosis, suggesting that Msx2 is the mediator of BMP4 action [42]. In rhombomeres that produce a significant number of CNCCs, the action of BMP is restricted by a Wnt antagonist, cSFRP2 [43]. Taken together, the patterning of CNCC formation within the neural tube is regulated by both positive and negative signals modulated by BMP. At later stages, Msx2 functions as a repressor of chondrogenesis without inducing cell death [44]. During migration, Msx2 and Sox9 are coexpressed in migrating CNCCs. Msx2 serves to repress the function of Sox9

such that these cells are allowed to migrate and arrive at their target site before overt differentiation occurs. A dominant negative form of Msx2 accelerates the rate and extent of chondrogenesis in CNCCs in cultures, demonstrating that, when the function of Msx2 is inhibited, cells are depressed, and allowed to differentiate [44]. Msx2 also functions as a repressor of chondrogenesis during the formation of Meckel's cartilage in the mandibular division of the first branchial arch [26]. Overexpression of Msx2 in the developing mandible disrupts the formation of Meckel's cartilage. Interestingly, Msx2 expression closely borders areas of cartilage differentiation and is tightly juxtaposed to the expression of Sox9. This suggests that Msx2 normally functions to delineate and define the boundaries for cartilage formation. Implanting BMP4-soaked beads in the developing mandible induces the expression of both Sox9 and Msx2 [26]. The relative level of expression of these antagonistic molecules, however, is dependent on positional cues within the mandible. These positional cues may be genes that are locally expressed in a specific region of the developing mandible. These genes may modify cellular competence to respond to BMP4, and consequently the expression pattern and profile of Sox9 and Msx2 induced by BMP4. It is this relative expression of Sox9 and Msx2 that determines whether ectopic cartilage will form around the bead. The regional molecular differences in the mandible that account for differential expression of Sox9 and Msx2 remain to be explored.

### Limb development

During skeletogenesis in the developing limb bud, chondrogenitor cells initiate their differentiation while neighboring cells undergo apoptosis, thus defining the boundaries of the developing skeletal elements. Mesenchymal condensations followed by chondrocyte differentiation and maturation occur in digital zones, whereas mesenchymal cells undergo apoptotic elimination in interdigital web zones to give rise to the delineation of the digits [45]. Failure of one of these processes results in limb malformations such as polydactyly or syndactyly of soft or hard tissues. BMPs regulate not only the chondrogenic and the apoptotic responses of the mesenchymal cells, but also specify digit identity, as well as participate in the generation, maintenance, and regression of the apical ectodermal ridge (a structure that governs the proximal-distal patterning of the limb bud) [46–48]. BMPs, however, do not pattern each region of the limb bud individually. Rather, evidence supports the hypothesis that BMPs participate in communicating cell fate decisions interactively between adjacent regions of the limb bud. Interdigital mesenchyme destined to undergo apoptosis *in vivo* produces cartilage when it is isolated away from the digits and developed *in vitro* [49,50]. Furthermore, digit identity is specified by the correspondingly more posterior interdigital tissue [48]. Interestingly, similar to the early patterning of the CNCC, Msx2 is also a mediator of BMP-

regulated apoptosis in the interdigital mesenchyme [51]. Recent data suggest that the specificity of BMP for multiple actions during limb morphogenesis reflects different activities of the receptor subtypes transducing the BMP signal [52]. BMP receptor type IB appears to be the necessary mediator of BMP-induced chondrogenesis [53–55], although overexpression of the receptor, or constitutive activation of the receptor can also cause excessive apoptosis [56,57]. A significant challenge of future research is to distinguish between the downstream signaling pathways from the BMP receptor subtypes. These differences may provide a molecular basis for the specific and often antithetic responses elicited by BMPs within developing limb buds and other tissues.


### Chondrocyte maturation

Embryonic cartilage is destined for one of several fates; it can remain as permanent cartilage, such as on the articular surfaces of bones, or it can provide a template for the formation of bones through the process of endochondral ossification (EO) [58,59]. Most of the bones of the axial and appendicular skeleton, and some of the bones of the craniofacial skeleton, develop through this process. The following two sections describe recent advances in understanding the molecular regulation of chondrocyte maturation during EO and joint formation.

### Endochondral ossification

The anlagen of long bones develop as relatively homogeneous elongated masses of cartilage tissue surrounded by a perichondrium. Signaling between the perichondrium and the chondrocytes (discussed below) causes cells in the center of the anlagen to initiate progression in their maturation program to prepare a site of ossification. These chondrocytes undergo several rounds of more rapid proliferation, and then arrest in their cell cycle. The postmitotic cells change their morphology, alter their gene expression, and remodel their extracellular matrix to become hypertrophic chondrocytes (Fig. 1). Whereas proliferating and articular chondrocytes synthesize a cartilage matrix composed mostly of type II collagen, hypertrophic chondrocytes cease expressing type II and express type X collagen, which is recognized as a marker of hypertrophic cells in the chondrocyte lineage. The cartilage matrix also becomes mineralized, and the hypertrophic chondrocytes undergo apoptosis. Prior to their death, they deposit the angiogenic factor, vascular endothelial growth factor (VEGF), into their extracellular matrix, which promotes the invasion of blood vessels into the cartilage tissue [60]. The blood vessels bring chondroclasts, osteoblasts and osteoclasts into the new ossification center, which begin removing the mineralized cartilage matrix and forming bone tissue.

The process of chondrocyte maturation expands from this initial central site toward the ends of the forming bones, with the zones of chondrocyte proliferation, cell cycle

**Figure 1**

A section through the growth plate of a fetal mouse metatarsal, 17 days post fertilization. Blue staining indicates endogenous alkaline phosphatase activity in the hypertrophic chondrocytes, diaphyseal perichondrium and bone collar, and primary spongiosa. Safranin O staining of chondromucin in the cartilage matrix is red. The regions populated by each stage of the chondrocyte lineage are shown.

arrest, hypertrophy, and apoptosis arranged sequentially (Fig. 1). The perichondrium along the shaft differentiates into a collar of bone that expands toward the ends of the developing bone in pace with the advance of hypertrophic chondrocytes. During postnatal development, these cartilage structures, called growth plates, are 'sandwiched' between the bony metaphysis and epiphysis, and serve as factories for the rapid production of new bone. Regulation and coordination of the rates of chondrocyte proliferation, hypertrophic maturation, apoptosis, and bone collar formation are essential to normal bone morphogenesis. Human genetic disorders affecting EO, such as achondroplasia and chondrodysplasias, are relatively common. Positional cloning in affected pedigrees has contributed to the identification of genes that regulate bone development [59,61–63]. Further analysis of the regulatory mechanisms in animal models has provided an understanding of the interactions of these genes. Recent advances in understanding the regulation of EO have resulted from the

studies of fibroblast growth factor receptors (FGFRs), Indian hedgehog (*lhh*), PTHrP, BMPs and core-binding factor (*Cbfa1*). Although retinoids, nitric oxide, hypoxia, vitamin D, estrogens, and other small molecules, as well as extracellular matrix molecules and biomechanical signals contribute to the regulation of chondrocyte differentiation and maturation, this review will focus primarily on peptide and glycoprotein growth factor signaling pathways.

### The PTHrP/*lhh* pathway

Chondrocyte proliferation and maturation in the growth plate is regulated by a negative feedback loop of intercellular communication, mediated by the secreted signaling molecules PTHrP and *lhh* [64,65]. PTHrP, a peptide hormone with homology to parathyroid hormone, is synthesized and secreted by periarticular perichondrial cells, and by chondrocytes later in development. It functions as a patterning molecule, inhibiting chondrocyte hypertrophy near the articular ends of the developing bone, thus maintaining a pool of proliferating cells [66]. Mutations in the PTH/PTHrP receptor that result in constitutive activation cause Jansen's chondrodysplasia [67]. These patients have decreased skeletal growth, abnormal metaphases and other skeletal malformations (OMIM 156400). *lhh*, a member of the hedgehog family of cell-surface-associated ligands is expressed in the postmitotic, prehypertrophic cells, and provides the signal to maintain PTHrP expression at the ends of the developing bone [65]. By inhibiting chondrocyte maturation, PTHrP downregulates *lhh* in the cells near the ends of the bone. *lhh* promotes chondrocyte proliferation and specifies growth in the long axis through PTHrP-dependent and PTHrP-independent mechanisms [68]. Loss of *lhh* function by gene targeting in mice results in decreased chondrocyte proliferation, loss of PTHrP expression, and abnormal positioning of hypertrophic chondrocytes close to the articular surface [66]. *lhh* is also necessary for the signaling between the postmitotic chondrocytes and the perichondrium to establish and advance the bone collar [66,69]. Point mutations in *lhh* that may inhibit binding to its receptor causes shortening of the digits (brachydactyly type A-1; OMIM 112500), consistent with its role in chondrocyte proliferation and bone growth [70].

### The BMP pathways

BMP6 may serve a direct role in regulating chondrocyte maturation, while other BMPs may contribute to signaling between the chondrocytes and the perichondrium. BMP6 is expressed in prehypertrophic and hypertrophic chondrocytes, and several other BMPs are expressed in the perichondrium [71–74]. Treatment of chondrogenic cultures with BMP6 promotes the expression of type X collagen and alkaline phosphatase [75]. Misexpression of constitutively active BMP receptor type IA in developing limbs, however, delays chondrocyte maturation, and like *lhh* overexpression, upregulates PTHrP [56,65]. This suggests that BMP stimulation of its receptor in the diaphy-



seal perichondrium mediates the signaling between *Ihh* from the prehypertrophic chondrocytes and PTHrP expression in the periarticular perichondrium.

### The fibroblast growth factor pathways

Of the high affinity receptors for fibroblast growth factors (FGFs), three of the five family members FGFR1, FGFR2 and FGFR3 regulate skeletal development. The importance of FGFR3 in regulating chondrocyte proliferation and maturation has been revealed by analysis of patients with activating mutations in this gene, which causes achondroplasia (OMIM 100800), hypochondroplasia (OMIM 146000), thanatophoric dysplasias (OMIM 187600), and other skeletal and soft tissue disorders, depending on the mutation (OMIM 134934)[63]. Su *et al.* [76] demonstrated that chondrocytes from a fetus with thanatophoric dysplasia type II exhibited increased activation of the transcription factor STAT1, and increased expression of the cyclin-dependent kinase inhibitor p21(Waf1/Cip1), a STAT-regulated gene. This suggests that mutations in FGFR cause defects in EO by inhibiting chondrocyte proliferation. Subsequent studies in mice and tissue culture cells have supported the hypothesis that increased FGFR activity disrupts the normal pattern of cartilage growth and maturation, at least in part by signaling through Stat molecules and increasing cyclin-dependent kinase inhibitor expression [77–82]. Furthermore, increased FGFR signaling causes premature apoptosis of growth plate chondrocytes in a Stat1-dependent manner [82,83]. Conversely, the FGFR3 null mutant mice exhibit increased chondrocyte proliferation and increased bone growth [84]. Interestingly, *Ihh* and PTHrP expression is decreased in mice expressing activated mutant FGFR3 or in wild type metatarsals grown in culture in the presence of FGF2 [85,86]. This suggests interactions between the FGF signaling pathway and the PTHrP/*Ihh* pathways in regulating chondrocyte proliferation and maturation, although the precise mechanisms of these interactions is not clear.

### The *Cbfa1* pathway

*Cbfa1* (also called *Runx2*, *PEBP2A* or *Osf2*; OMIM 600211) is a critical gene in the regulation of skeletal development as it is necessary for endochondral and intramembranous bone formation, and it is sufficient to induce premature and ectopic chondrocyte hypertrophy [87–90]. *Cbfa1* encodes a transcription factor containing a conserved runt domain, that is expressed in mesenchymal condensations, chondrocytes, and cells of the osteoblast lineage [90–93]. Heterozygous loss of function mutations in *Cbfa1* cause cleidocranial dysplasia (OMIM 119600), a syndrome that includes clavicle hypoplasia or aplasia, failure in closure of the anterior fontanel, and other skeletal and dental malformations [94]. In addition to the essential role that *Cbfa1* plays in osteoblast differentiation, it also regulates chondrocyte maturation. Loss of *Cbfa1* by gene targeting in mice

results in a complete lack of bone formation and a lack of chondrocyte hypertrophy in most of the skeleton [87,88,92,93]. Ectopic expression of *Cbfa1* in nonhypertrophic chondrocytes of transgenic mice promotes their hypertrophic differentiation and disrupts joint formation [90,95]. *Cbfa1* is a direct regulator of osteocalcin and other genes in osteoblasts, and may also directly regulate hypertrophic-chondrocyte-specific genes [89]. VEGF, which is normally expressed in hypertrophic chondrocytes, is not expressed in the chondrocytes of *Cbfa1* null mutant mice. Furthermore, VEGF expression is upregulated by *Cbfa1* in fibroblasts in tissue culture [96]. These data suggest that *Cbfa1* is an important regulator of EO, controlling chondrocyte maturation, osteoblast differentiation, and angiogenesis in the developing bone.

The regulation of *Cbfa1* expression and activity serves as a point of convergence of multiple signaling pathways. *Cbfa1* expression is upregulated by BMP2, BMP4 or BMP7 treatment of multipotential, skeletal, or myogenic cell lines [91,97–99]. The regulation of *Cbfa1* by BMP may be mediated by *Msx2*, since *Cbfa1* expression is decreased in *Msx2* null mutant mice [39]. Negative regulators of *Cbfa1* expression in osteogenic cells include glucocorticoid, 1,25(OH)<sub>2</sub>D<sub>3</sub>, and TGF-β [91,100,101]. The function of *Cbfa1* is repressed by its association with Smad3 in TGF-β stimulated cells [101]. *Cbfa1* expression is upregulated in transgenic mice carrying an activated mutant FGFR1, and upregulated in a mesenchymal cell line treated with FGF2 or FGF8 [102]. *Ihh* may be both a regulator of *Cbfa1* expression and a target of *Cbfa1* transcriptional activity. *Cbfa1* expression and bone collar formation is dependent on *Ihh* expression in prehypertrophic chondrocytes [66,69]. Expression of *Cbfa1* in nonhypertrophic chondrocytes induces *Ihh* expression in these cells and eventual hypertrophy [90,95]. Further study of the regulation of *Cbfa1*, its protein interactions, and the targets of its transcriptional activity will contribute to the detailed characterization of the molecular mechanisms regulating EO.

### Joint formation

Another fate for embryonic skeletal cartilage is the formation of joints. The cartilage template for the developing limb skeleton forms as a continuous, branched cartilage element from the humerus/femur to the digit rays, with only a few skeletal elements formed from independent condensations [103,104]. These cartilage structures are then segmented through the differentiation and apoptosis of chondrocytes to form joint cavities, through a process called cavitation. Concurrently, adjacent chondrocytes and perichondrial cells differentiate to form articular cartilage and other joint-associated tissues [105,106].

Cartilage-derived morphogenetic protein 1 (CDMP1) and its mouse homologue, *Gdf5*, are members of the TGF-β

superfamily, related to BMPs. Null mutation of *Gdf5* causes shortening of the digits and defects in joint formation in the limbs as seen in the classical mouse mutant line brachypodism (*bp*) [105,107]. Mutations in *CDMP1* cause the human skeletal disorders Grebe type chondrodysplasia (OMIM 200700), Hunter-Thompson type acromesomelic dysplasia (OMIM 201250) and brachydactyly type C (OMIM 113100), which all include shortened or missing phalanges. *Gdf5* is normally expressed in developing joints. It is one of the earliest markers of joint formation and is strongly expressed throughout cavitation [108–110]. *Gli3*, a transcription factor that functions in the hedgehog signaling pathway, is also expressed in developing joints, and its expression pattern is expanded in *bp* mice [110]. Focal application of exogenous *Gdf5* protein to the cartilage digit rays of *bp* mouse limb buds in culture inhibits the expanded expression of *Gli3* [110]. This suggests that *CDMP1/Gdf5* provides an important signal for the sites of joint formation, and this signal regulates the expression of genes that control chondrocyte differentiation.

Recent studies by Hartmann and Tabin [111] demonstrated the importance of Wnt-14 in initiating joint formation and in the spacing of joints within the cartilage condensation. Wnt-14 is a member of the large Wnt family of secreted glycoproteins that bind to receptors of the frizzled family. Wnt-14 is expressed in the early joint-forming regions of the developing chicken limb in a pattern similar to *Gdf5*. In fully developed joints, however, Wnt-14 is expressed in the joint capsule and synovial membrane, while *Gdf5* is restricted to the joint fibroarticular cartilage. Ectopic expression of Wnt-14 in developing digits induces morphological and molecular changes indicative of ectopic joint formation, including inhibition of cartilage differentiation, and upregulation of *Gli3*, *Gdf5*, autotaxin, chordin, Wnt-4 and CD44rel expression in relative patterns similar to those seen in normal joint development [111]. Furthermore, ectopic Wnt-14 expression represses adjacent endogenous joint development in the same cartilage condensation. This suggests that joint initiation by Wnt-14 activates a signal that regulates the positioning of the next joint in the patterning of the digits.

Study of the Wnt/frizzled pathway will contribute to an understanding of skeletal patterning and joint formation and may also provide molecular characterization of cellular changes in rheumatoid arthritis. Wnt-5a and frizzled 5 are both overexpressed in the synovial tissues of rheumatoid arthritis patients when compared to normal joint tissue or tissue from osteoarthritic joints [112]. This may suggest a change in the state of differentiation of synoviocytes that contributes to progression of the disease.

### Future directions

Skeletal morphogenesis depends greatly on the patterning and formation of cartilage, and the subsequent remodeling

of cartilage into bones or joints. Molecules such as BMPs regulate important steps at different times in the life cycle of cartilage. This may suggest that BMPs instruct chondrocytes when to change their patterns of gene expression and behavior rather than providing specific instructions of which genes to express. The set of genes ready for expression may be determined by the history of signals to which the cell has been exposed, and the collection of receptors, signaling molecules and transcription factors accumulated in response to those signals. During chondrogenesis and endochondral ossification, chondrocyte proliferation is regulated by FGFs, BMPs, PTHrP, *Ihh*, cell–cell and cell–matrix adhesion, and biomechanical signals. These multiple concurrent signals converge on the regulation of cell cycle progression and cell differentiation. Further study of the interaction of cartilage-associated transcription factors such as *Msx2* and *Cbfa1* with cell-cycle regulators will contribute to an understanding of the important connection between proliferation and differentiation. Tissue engineering for the treatment of skeletal diseases and disorders will depend on effective tools for expanding populations of chondrocytes while maintaining or restoring their state of differentiation.

### Acknowledgements

We are grateful to Harold C Slavkin for bringing our research together and for providing continued encouragement and guidance. We thank Alan Horner for critical reading of the manuscript and Sirinee Chiamvichit for assisting in the preparation of the manuscript. Barbara Schmitt provided valuable assistance in compiling the information for Table I. Lillian Shum and Glen Nuckolls are supported by NIH Z01-AR41114.

### References

- Nuckolls GH, Shum L, Slavkin HC: **Progress toward understanding craniofacial malformations.** *Cleft Palate Craniofac J* 1999, **36**:12-26.
- Felson DT, Lawrence RC, Dieppe PA, Hirsch R, Helmick CG, Jordan JM, Kington RS, Lane NE, Nevitt MC, Zhang Y, Sowers M, McAlindon T, Spector TD, Poole AR, Yanovski SZ, Ateshian G, Sharma L, Buckwalter JA, Brandt KD, Fries JF: **Osteoarthritis: new insights. Part 1: the disease and its risk factors.** *Ann Intern Med* 2000, **133**:635-646.
- Loughlin J: **Genetic epidemiology of primary osteoarthritis.** *Curr Opin Rheumatol* 2001, **13**:111-116.
- Hill DJ, Logan A: **Peptide growth factors and their interactions during chondrogenesis.** *Prog Growth Factor Res* 1992, **4**:45-68.
- Underhill TM, Sampaio AV, Weston AD: **Retinoid signalling and skeletal development.** *Novartis Found Symp* 2001, **232**:171-185.
- Mundlos S, Olsen BR: **Heritable diseases of the skeleton. Part I: Molecular insights into skeletal development-transcription factors and signaling pathways.** *Faseb J* 1997, **11**:125-132.
- Mundlos S, Olsen BR: **Heritable diseases of the skeleton. Part II: Molecular insights into skeletal development-matrix components and their homeostasis.** *Faseb J* 1997, **11**:227-233.
- Wu W, Mwale F, Tchetina E, Kojima T, Yasuda T, Poole AR: **Cartilage matrix resorption in skeletogenesis.** *Novartis Found Symp* 2001, **232**:158-166.
- DeLise AM, Fischer L, Tuan RS: **Cellular interactions and signaling in cartilage development.** *Osteoarthritis Cartilage* 2000, **8**:309-334.
- Daniels K, Solursh M: **Modulation of chondrogenesis by the cytoskeleton and extracellular matrix.** *J Cell Sci* 1991, **100**:249-254.
- Hasler EM, Herzog W, Wu JZ, Muller W, Wyss U: **Articular cartilage biomechanics: theoretical models, material properties,**

- and biosynthetic response. *Crit Rev Biomed Eng* 1999, **27**: 415-488.
12. Reddi AH: **Morphogenesis and tissue engineering of bone and cartilage: inductive signals, stem cells, and biomimetic biomaterials.** *Tissue Eng* 2000, **6**:351-359.
  13. Hall BK, Miyake T: **All for one and one for all: condensations and the initiation of skeletal development.** *Bioessays* 2000, **22**:138-147.
  14. Haas AR, Tuan RS: **Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: II. Stimulation by bone morphogenetic protein-2 requires modulation of N-cadherin expression and function.** *Differentiation* 1999, **64**:77-89.
  15. Stott NS, Jiang TX, Chuong CM: **Successive formative stages of precartilaginous mesenchymal condensations in vitro: modulation of cell adhesion by Wnt-7A and BMP-2.** *J Cell Physiol* 1999, **180**:314-324.
  16. Oh CD, Chang SH, Yoon YM, Lee SJ, Lee YS, Kang SS, Chun JS: **Opposing role of mitogen-activated protein kinase subtypes, erk-1/2 and p38, in the regulation of chondrogenesis of mesenchymes.** *J Biol Chem* 2000, **275**:5613-5619.
  17. Urist MR: **Bone: formation by autoinduction.** *Science* 1965, **150**:893-899.
  18. Ducy P, Karsenty G: **The family of bone morphogenetic proteins.** *Kidney Int* 2000, **57**:2207-2214.
  19. Wozney JM: **The bone morphogenetic protein family: multifunctional cellular regulators in the embryo and adult.** *Eur J Oral Sci* 1998, **106**:160-166.
  20. Miyazono K, Kusanagi K, Inoue H: **Divergence and convergence of TGF-beta/BMP signaling.** *J Cell Physiol* 2001, **187**:265-276.
  21. Wrana JL: **Regulation of Smad activity.** *Cell* 2000, **100**:189-192.
  22. Reddi AH: **Cartilage morphogenesis: role of bone and cartilage morphogenetic proteins, homeobox genes and extracellular matrix.** *Matrix Biol* 1995, **14**:599-606.
  23. Reddi AH: **Interplay between bone morphogenetic proteins and cognate binding proteins in bone and cartilage development: noggin, chordin and DAN.** *Arthritis Res* 2001, **3**:1-5.
  24. Healy C, Uwanogho D, Sharpe PT: **Regulation and role of Sox9 in cartilage formation.** *Dev Dyn* 1999, **215**:69-78.
  25. Zehentner BK, Dony C, Burtscher H: **The transcription factor Sox9 is involved in BMP-2 signaling.** *J Bone Miner Res* 1999, **14**:1734-1741.
  26. Semba I, Nonaka K, Takahashi I, Takahashi K, Dashner R, Shum L, Nuckolls GH, Slavkin HC: **Positionally-dependent chondrogenesis induced by BMP4 is co-regulated by Sox9 and Msx2.** *Dev Dyn* 2000, **217**:401-414.
  27. Wheatley S, Wright E, Jeske Y, McCormack A, Bowles J, Koopman P: **Aetiology of the skeletal dysmorphism syndrome campomelic dysplasia: expression of the Sox9 gene during chondrogenesis in mouse embryos.** *Ann N Y Acad Sci* 1996, **785**:350-352.
  28. Lefebvre V, de Crombrugge B: **Toward understanding SOX9 function in chondrocyte differentiation.** *Matrix Biol* 1998, **16**: 529-540.
  29. Xie WF, Zhang X, Sakano S, Lefebvre V, Sandell LJ: **Trans-activation of the mouse cartilage-derived retinoic acid-sensitive protein gene by Sox9.** *J Bone Miner Res* 1999, **14**:757-763.
  30. de Crombrugge B, Lefebvre V, Behringer RR, Bi W, Murakami S, Huang W: **Transcriptional mechanisms of chondrocyte differentiation.** *Matrix Biol* 2000, **19**:389-394.
  31. Bi W, Deng JM, Zhang X, Behringer RR, de Crombrugge B: **Sox9 is required for cartilage formation.** *Nat Genet* 1999, **22**: 85-89.
  32. Bi W, Huang W, Whitworth DJ, Deng JM, Zhang Z, Behringer RR, de Crombrugge B: **Haploinsufficiency of Sox9 results in defective cartilage primordia and premature skeletal mineralization.** *Proc Natl Acad Sci USA* 2001, **98**:6698-6703.
  33. Huang W, Chung UI, Kronenberg HM, de Crombrugge B: **The chondrogenic transcription factor Sox9 is a target of signaling by the parathyroid hormone-related peptide in the growth plate of endochondral bones.** *Proc Natl Acad Sci USA* 2001, **98**:160-165.
  34. Huang W, Zhou X, Lefebvre V, de Crombrugge B: **Phosphorylation of SOX9 by cyclic AMP-dependent protein kinase A enhances SOX9's ability to transactivate a Col2a1 chondrocyte-specific enhancer.** *Mol Cell Biol* 2000, **20**:4149-4158.
  35. Lefebvre V, Li P, de Crombrugge B: **A new long form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondrogenesis and cooperatively activate the type II collagen gene.** *EMBO J* 1998, **17**:5718-5733.
  36. Nuckolls GH, Slavkin HC, Shum L: **Bone morphogenetic protein signaling in limb and craniofacial development.** In *Proceedings of the Biological Mechanisms of Tooth Eruption, Resorption and Replacement by Implants.* Edited by Davidowitch Z. Birmingham, AL: Harvard Society for the Advancement of Orthodontics, EBSCO media; 1998:39-47.
  37. Shum L, Takahashi K, Takahashi I, Nagata M, Tan DP, Semba I, Tanaka O, Bringas P, Nuckolls GH, Slavkin HC: **Embryogenesis and the classification of craniofacial dysmorphogenesis.** In *Oral and Maxillofacial Surgery.* Edited by Fonseca RJ. Philadelphia: WB Saunders; 2000:149-194.
  38. Bendall AJ, Abate-Shen C: **Roles for Msx and Dlx homeoproteins in vertebrate development.** *Gene* 2000, **247**:17-31.
  39. Satokata I, Ma L, Ohshima H, Bei M, Woo I, Nishizawa K, Maeda T, Takano Y, Uchiyama M, Heaney S, Peters H, Tang Z, Maxson R, Maas R: **Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation.** *Nat Genet* 2000, **24**:391-395.
  40. Wilkie AO, Oldridge M, Tang Z, Maxson RE Jr: **Craniosynostosis and related limb anomalies.** *Novartis Found Symp* 2001, **232**: 122-133.
  41. Graham A, Francis-West P, Brickell P, Lumsden A: **The signalling molecule BMP4 mediates apoptosis in the rhombencephalic neural crest.** *Nature* 1994, **372**:684-686.
  42. Takahashi K, Nuckolls GH, Tanaka O, Semba I, Takahashi I, Dashner R, Shum L, Slavkin HC: **Adenovirus-mediated ectopic expression of Msx2 in even-numbered rhombomeres induces apoptotic elimination of cranial neural crest cells in ovo.** *Development* 1998, **125**:1627-1635.
  43. Ellies DL, Church V, Francis-West P, Lumsden A: **The WNT antagonist cSFRP2 modulates programmed cell death in the developing hindbrain.** *Development* 2000, **127**:5285-5295.
  44. Takahashi K, Nuckolls GH, Takahashi I, Nonaka K, Nagata M, Ikura T, Slavkin HC, Shum L: **Msx2 is a repressor of chondrogenic differentiation in migratory cranial neural crest cells.** *Dev Dynamics* 2001, **222**:252-262.
  45. Pizette S, Niswander L: **Early steps in limb patterning and chondrogenesis.** *Novartis Found Symp* 2001, **232**:23-36.
  46. Dahn RD, Fallon JF: **Limiting outgrowth: BMPs as negative regulators in limb development.** *Bioessays* 1999, **21**:721-725.
  47. Merino R, Ganam Y, Macias D, Rodriguez-Leon J, Hurler JM: **Bone morphogenetic proteins regulate interdigital cell death in the avian embryo.** *Ann N Y Acad Sci* 1999, **887**:120-132.
  48. Dahn RD, Fallon JF: **Interdigital regulation of digit identity and homeotic transformation by modulated BMP signaling.** *Science* 2000, **289**:438-441.
  49. Ros MA, Piedra ME, Fallon JF, Hurler JM: **Morphogenetic potential of the chick leg interdigital mesoderm when diverted from the cell death program.** *Dev Dyn* 1997, **208**:406-419.
  50. Tang MK, Leung AK, Kwong WH, Chow PH, Chan JY, Ngo-Muller V, Li M, Lee KK: **Bmp-4 requires the presence of the digits to initiate programmed cell death in limb interdigital tissues.** *Dev Biol* 2000, **218**:89-98.
  51. Ferrari D, Lichtler AC, Pan ZZ, Dealy CN, Upholt WB, Kosher RA: **Ectopic expression of Msx-2 in posterior limb bud mesoderm impairs limb morphogenesis while inducing BMP-4 expression, inhibiting cell proliferation, and promoting apoptosis.** *Dev Biol* 1998, **197**:12-24.
  52. Cheifetz S: **BMP receptors in limb and tooth formation.** *Crit Rev Oral Biol Med* 1999, **10**:182-198.
  53. Nonaka K, Shum L, Takahashi I, Takahashi K, Ikura T, Dashner R, Nuckolls GH, Slavkin HC: **Convergence of the BMP and EGF signaling pathways on Smad1 in the regulation of chondrogenesis.** *Int J Dev Biol* 1999, **43**:795-807.
  54. Baur ST, Mai JJ, Dymecki SM: **Combinatorial signaling through BMP receptor IB and GDF5: shaping of the distal mouse limb and the genetics of distal limb diversity.** *Development* 2000, **127**:605-619.
  55. Yi SE, Daluiski A, Pederson R, Rosen V, Lyons KM: **The type I BMP receptor BMPRII is required for chondrogenesis in the mouse limb.** *Development* 2000, **127**:621-630.
  56. Zou H, Wieser R, Massague J, Niswander L: **Distinct roles of type I bone morphogenetic protein receptors in the formation**

- and differentiation of cartilage. *Genes Dev* 1997, **11**:2191-2203.
57. Zhang Z, Yu X, Zhang Y, Geronimo B, Lovlie A, Fromm SH, Chen Y: Targeted misexpression of constitutively active BMP receptor-IB causes bifurcation, duplication, and posterior transformation of digit in mouse limb. *Dev Biol* 2000, **220**: 154-167.
  58. Erlebacher A, Filvaroff EH, Gitelman SE, Derynck R: Toward a molecular understanding of skeletal development. *Cell* 1995, **80**:371-378.
  59. Olsen BR, Reginato AM, Wang W: Bone Development. *Annu Rev Cell Dev Biol* 2000, **16**:191-220.
  60. Gerber HP, Vu TH, Ryan AM, Kowalski J, Werb Z, Ferrara N: VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. *Nat Med* 1999, **5**:623-628.
  61. Francomano CA, McIntosh I, Wilkin DJ: Bone dysplasias in man: molecular insights. *Curr Opin Genet Dev* 1996, **6**:301-308.
  62. Mundlos S, Olsen BR: Heritable diseases of the skeleton. Part II: Molecular insights into skeletal development-matrix components and their homeostasis. *FASEB J* 1997, **11**:227-233.
  63. Vajo Z, Francomano CA, Wilkin DJ: The molecular and genetic basis of fibroblast growth factor receptor 3 disorders: the achondroplasia family of skeletal dysplasias, Muenke craniosynostosis, and Crozon syndrome with acanthosis nigricans. *Endocr Rev* 2000, **21**:23-39.
  64. Lanske B, Karaplis AC, Lee K, Luz A, Vortkamp A, Pirro A, Karperien M, Defize LH, Ho C, Mulligan RC, Abou-Samra AB, Juppner H, Segre GV, Kronenberg HM: PTH/PTHrP receptor in early development and Indian hedgehog-regulated bone growth. *Science* 1996, **273**:663-666.
  65. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ: Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. *Science* 1996, **273**:613-622.
  66. St-Jacques B, Hammerschmidt M, McMahon AP: Indian hedgehog signaling regulates proliferation and differentiation of chondrocytes and is essential for bone formation. *Genes Dev* 1999, **13**:2072-2086.
  67. Schipani E, Kruse K, Juppner H: A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. *Science* 1995, **268**:98-100.
  68. Karp SJ, Schipani E, St-Jacques B, Hunzelman J, Kronenberg H, McMahon AP: Indian hedgehog coordinates endochondral bone growth and morphogenesis via parathyroid hormone related-protein-dependent and -independent pathways. *Development* 2000, **127**:543-548.
  69. Chung UI, Schipani E, McMahon AP, Kronenberg HM: Indian hedgehog couples chondrogenesis to osteogenesis in endochondral bone development. *J Clin Invest* 2001, **107**:295-304.
  70. Gao B, Guo J, She C, Shu A, Yang M, Tan Z, Yang X, Guo S, Feng G, He L: Mutations in IHH, encoding Indian hedgehog, cause brachydactyly type A-1. *Nat Genet* 2001, **28**:386-388.
  71. Lyons KM, Pelton RW, Hogan BL: Organogenesis and pattern formation in the mouse: RNA distribution patterns suggest a role for bone morphogenetic protein-2A (BMP-2A). *Development* 1990, **109**:833-844.
  72. Jones CM, Lyons KM, Hogan BL: Involvement of Bone Morphogenetic Protein-4 (BMP-4) and Vgr-1 in morphogenesis and neurogenesis in the mouse. *Development* 1991, **111**:531-542.
  73. Kingsley DM: What do BMPs do in mammals? Clues from the mouse short-ear mutation. *Trends Genet* 1994, **10**:16-21.
  74. Pathi S, Rutenberg JB, Johnson RL, Vortkamp A: Interaction of Ihh and BMP/Noggin signaling during cartilage differentiation. *Dev Biol* 1999, **209**:239-253.
  75. Grimsrud CD, Romano PR, D'Souza M, Puzas JE, Reynolds PR, Rosier RN, O'Keefe RJ: BMP-6 is an autocrine stimulator of chondrocyte differentiation. *J Bone Miner Res* 1999, **14**:475-482.
  76. Su WC, Kitagawa M, Xue N, Xie B, Garofalo S, Cho J, Deng C, Horton WA, Fu XY: Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. *Nature* 1997, **386**:288-292.
  77. Chen L, Adar R, Yang X, Monsonogo EO, Li C, Hauschka PV, Yayon A, Deng CX: Gly369Cys mutation in mouse FGFR3 causes achondroplasia by affecting both chondrogenesis and osteogenesis. *J Clin Invest* 1999, **104**:1517-1525.
  78. Li C, Chen L, Iwata T, Kitagawa M, Fu XY, Deng CX: A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. *Hum Mol Genet* 1999, **8**:35-44.
  79. Sahni M, Ambrosetti DC, Mansukhani A, Gertner R, Levy D, Basilico C: FGF signaling inhibits chondrocyte proliferation and regulates bone development through the STAT-1 pathway. *Genes Dev* 1999, **13**:1361-1366.
  80. Hart KC, Robertson SC, Kanemitsu MY, Meyer AN, Tynan JA, Donoghue DJ: Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. *Oncogene* 2000, **19**:3309-3320.
  81. Aikawa T, Segre GV, Lee K: Fibroblast growth factor inhibits chondrocyte growth through induction of p21 and subsequent inactivation of Cyclin E-Cdk2. *J Biol Chem* 2001, **276**: 29347-29352.
  82. Sahni M, Raz R, Coffin JD, Levy D, Basilico C: STAT1 mediates the increased apoptosis and reduced chondrocyte proliferation in mice overexpressing FGF2. *Development* 2001, **28**: 2119-2129.
  83. Legeai-Mallet L, Benoist-Lasselin C, Delezoide AL, Munnich A, Bonaventure J: Fibroblast growth factor receptor 3 mutations promote apoptosis but do not alter chondrocyte proliferation in thanatophoric dysplasia. *J Biol Chem* 1998, **273**:13007-13014.
  84. Deng C, Wynshaw-Boris A, Zhou F, Kuo A, Leder P: Fibroblast growth factor receptor 3 is a negative regulator of bone growth. *Cell* 1996, **84**:911-921.
  85. Naski MC, Colvin JS, Coffin JD, Ornitz DM: Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3. *Development* 1998, **125**:4977-4988.
  86. Chen L, Li C, Qiao W, Xu X, Deng C: A Ser(365)->Cys mutation of fibroblast growth factor receptor 3 in mouse downregulates Ihh/PTHrP signals and causes severe achondroplasia. *Hum Mol Genet* 2001, **10**:457-465.
  87. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, Sato M, Okamoto R, Kitamura Y, Yoshiki S, Kishimoto T: Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell* 1997, **89**:755-764.
  88. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, Selby PB, Owen MJ: Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell* 1997, **89**:765-771.
  89. Ducy P: Cbfa1: a molecular switch in osteoblast biology. *Dev Dyn* 2000, **219**:461-471.
  90. Takeda S, Bonnamy JP, Owen MJ, Ducy P, Karsenty G: Continuous expression of Cbfa1 in nonhypertrophic chondrocytes uncovers its ability to induce hypertrophic chondrocyte differentiation and partially rescues Cbfa1-deficient mice. *Genes Dev* 2001, **15**:467-481.
  91. Ducy P, Zhang R, Geoffroy V, Ridall AL, Karsenty G: Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. *Cell* 1997, **89**:747-754.
  92. Inada M, Yasui T, Nomura S, Miyake S, Deguchi K, Himeno M, Sato M, Yamagiwa H, Kimura T, Yasui N, Ochi T, Endo N, Kitamura Y, Kishimoto T, Komori T: Maturation disturbance of chondrocytes in Cbfa1-deficient mice. *Dev Dyn* 1999, **214**: 279-290.
  93. Kim IS, Otto F, Zabel B, Mundlos S: Regulation of chondrocyte differentiation by Cbfa1. *Mech Dev* 1999, **80**:159-170.
  94. Mundlos S, Otto F, Mundlos C, Mulliken JB, Aylsworth AS, Albright S, Lindhout D, Cole WG, Henn W, Knoll JH, Owen MJ, Mertelsmann R, Zabel BU, Olsen BR: Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. *Cell* 1997, **89**:773-779.
  95. Ueta C, Iwamoto M, Kanatani N, Yoshida C, Liu Y, Enomoto-Iwamoto M, Ohmori T, Enomoto H, Nakata K, Takada K, Kurisu K, Komori T: Skeletal malformations caused by overexpression of Cbfa1 or its dominant negative form in chondrocytes. *J Cell Biol* 2001, **153**:87-100.
  96. Zelzer E, Glotzer DJ, Hartmann C, Thomas D, Fukai N, Soker S, Olsen BR: Tissue specific regulation of VEGF expression during bone development requires Cbfa1/Runx2. *Mech Dev* 2001, **106**:97-106.

97. Tsuji K, Ito Y, Noda M: **Expression of the PEBP2alphaA/AML3/CBFA1 gene is regulated by BMP4/7 heterodimer and its overexpression suppresses type I collagen and osteocalcin gene expression in osteoblastic and nonosteoblastic mesenchymal cells.** *Bone* 1998, **22**:87-92.
98. Gori F, Thomas T, Hicok KC, Spelsberg TC, Riggs BL: **Differentiation of human marrow stromal precursor cells: bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation.** *J Bone Miner Res* 1999, **14**:1522-1535.
99. Lee MH, Javed A, Kim HJ, Shin HI, Gutierrez S, Choi JY, Rosen V, Stein JL, van Wijnen AJ, Stein GS, Lian JB, Ryoo HM: **Transient upregulation of CBFA1 in response to bone morphogenetic protein-2 and transforming growth factor beta 1 in C2C12 myogenic cells coincides with suppression of the myogenic phenotype but is not sufficient for osteoblast differentiation.** *J Cell Biochem* 1999, **73**:114-125.
100. Chang DJ, Ji C, Kim KK, Casinighino S, McCarthy TL, Centrella M: **Reduction in transforming growth factor beta receptor I expression and transcription factor CBFA1 on bone cells by glucocorticoid.** *J Biol Chem* 1998, **273**:4892-4896.
101. Alliston T, Choy L, Ducey P, Karsenty G, Derynck R: **TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation.** *EMBO J* 2001, **20**:2254-2272.
102. Zhou YX, Xu X, Chen L, Li C, Brodie SG, Deng CX: **A Pro250Arg substitution in mouse Fgfr1 causes increased expression of Cbfa1 and premature fusion of calvarial sutures.** *Hum Mol Genet* 2000, **9**:2001-2008.
103. Shubin NH, Alberch P: **A morphogenetic approach to the origin and basic organization of the tetrapod limb.** *Evol Biol* 1986, **20**:319-387.
104. Oster GF, Shubin N, Murray JD, Alberch P: **Evolution and morphogenetic rules: the shape of the vertebrate limb in ontogeny and phylogeny.** *Evolution* 1988, **42**:862-884.
105. Kingsley DM: **Genetic control of bone and joint formation.** *Novartis Found Symp* 2001, **232**:213-22.
106. Pacifici M, Koyama E, Iwamoto M, Gentili C: **Development of articular cartilage: what do we know about it and how may it occur?** *Connect Tissue Res* 2000, **41**:175-184.
107. Storm EE, Huynh TV, Copeland NG, Jenkins NA, Kingsley DM, Lee SJ: **Limb alterations in brachypodism mice due to mutations in a new member of the TGF beta-superfamily.** *Nature* 1994, **368**:639-643.
108. Storm EE, Kingsley DM: **Joint patterning defects caused by single and double mutations in members of the bone morphogenetic protein (BMP) family.** *Development* 1996, **122**:3969-3979.
109. Wolfman NM, Hattersley G, Cox K, Celeste AJ, Nelson R, Yamaji N, Dube JL, DiBlasio-Smith E, Nove J, Song JJ, Wozney JM, Rosen V: **Ectopic induction of tendon and ligament in rats by growth and differentiation factors 5, 6, and 7, members of the TGF-beta gene family.** *J Clin Invest* 1997, **100**:321-330.
110. Storm EE, Kingsley DM: **GDF5 coordinates bone and joint formation during digit development.** *Dev Biol* 1999, **209**:11-27.
111. Hartmann C, Tabin CJ: **Wnt-14 plays a pivotal role in inducing synovial joint formation in the developing appendicular skeleton.** *Cell* 2001, **104**:341-351.
112. Sen M, Lauterbach K, El-Gabalawy H, Firestein GS, Corr M, Carson DA: **Expression and function of wingless and frizzled homologs in rheumatoid arthritis.** *Proc Natl Acad Sci USA* 2000, **97**:2791-2796.
113. Online Mendelian Inheritance in Man. McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University (Baltimore, MD) and National Center for Biotechnology Information, National Library of Medicine (Bethesda, MD); 2000 [<http://www.ncbi.nlm.nih.gov/omim/>].